NEWS AND PUBLICATIONS
Links open as PDF’s unless otherwise indicated
- Justin Barber et al, CSF Markers of Preclinical Alzheimer’s and Deficits on a Self-Administered Computerized Test Battery, July 26, 2018
University of Kentucky, Lexington, KY, AAIC 2018 Abstract ID: 25554
In a multi-year study of 81 adults, conducted by the Kentucky Neuroscience Institute, the CANS-MCI has been shown to be sensitive to heightened levels of Aβ and tau in cerebral spinal fluid.
- Infections and Alzheimer’s. May 27, 2016: Insights Give Hope for New Attack on Alzheimer’s
Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, Moir RD. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med. 2016 May 25;8 (340)
The plaques that accumulate in the brain fight infection as part of the normal immune system. Since the barrier to brain infection deteriorates with age, the excess accumulation of plaques may relate to that function (and counteracting such accumulation might eventually be accomplished in novel, related ways). The CANS-MCI is ideally suited for the earliest economical detection of those changes in cognition most relevant to the timing of such prevention efforts.
- Memória CM, Yassuda MS, Nakano EY, Forlenza OV. Contributions of the Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI) for the diagnosis of MCI in Brazil. Int Psychogeriatr. 2014 May 7:1-9.
This study confirmed the factor structure of the CANS-MCI and, despite new country- and language-specific properties, the Brazilian version “maintains psychometric characteristics that render it suitable to identify elderly adults with probable cognitive impairment to whom a more extensive evaluation by formal neuropsychological tests may be required.”
- The 2012 Alzheimer’s Association International Conference in Vancouver, BC, Canada, study by James Scanlan, PhD
Using the CANS-MCI Dr. Scanlan shows that “Self-reported memory fails to substitute for objective memory measures”. This study provided evidence that clinicians using subjective patient memory concerns as substitutes for objective testing will frequently be misguided. Additionally, using a questionnaire designed for caregivers directly with patients is contra-indicated. Additional evidence was also provided that the CANS-MCI has good agreement with both the Mattis Dementia Rating and the Weschler Memory Scales.
- In 2011, the Journal Alzheimer’s & Dementia published a comparison of all computerized tests for cognitive decline, emphasizing sensitivity and specificity, which described the CANS-MCI the most favorably with respect to primary care applicability
Snyder, PJ, Jackson, CE, Petersen, RC, Khachaturian, AS, Kaye, Albert, MS, and Weintraub, S Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer’s & Dementia, 7, 338-355, 2011.
“The Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI; Screen, Inc. Seattle, WA) was developed specifically to meet the needs of primary care physicians, and it includes an assessment of cognition, mood, health history and risk factors, substance use and driving capabilities. The assessment of cognition includes measures of free and guided recall, delayed free and guided recognition, primed picture naming, word-to-picture matching, design matching, clock hand placement and the Stroop Test. For individuals with a high school education or less, the CANS-MCI showed sensitivity of 100% and specificity of 100%, indicating that it correctly identified all participants as either meeting criteria for MCI or as a healthy control. For individuals with 13 or more years of education, the CANS-MCI showed sensitivity of 100% and specificity of 84.8%, with an AUC of 0.96.”
- The New York Times: With Alzheimer’s Patients Growing in Number, Congress Endorses a National Plan
The NY Times reports that Congress has unanimously voted to create a National Plan to combat Alzheimer’s Disease with the same intensity as the attacks on AIDS and cancer. Early Detection and treatment will be the focus of this effort.
- The New York Times: Insights Give Hope for New Attack on Alzheimer’s
Recently an excellent article by Gina Kolata summarizes the most recent insights that will lead to prevention or treatment for Alzheimer’s. The CANS-MCI is ideally suited for the earliest economical detection of those changes in cognition most relevant to the timing of prevention and treatment.
- Celeste A de Jager, Samrah Ahmed-Ali, & Gordon K Wilcock. A comparison of screening tools for the assessment of Mild Cognitive Impairment
Alzheimer’s and Dementia, Volume 6, Issue 4, Supplement, Page S354, July 2010.
This independent United Kingdom study of the CANS-MCI, the ACE-R, the MMSE, and the MoCA established the CANS-MCI as the computer-administered testing alternative with highest sensitivity and specificity for the discrimination between normal elderly and MCI.
- Newsweek.com: The Pen is Mightier Than the MRI
This independent review of fast, reliable, and affordable tests for Alzheimer’s singled out Screen, Inc’s CANS-MCI as the computerized test for MCI (Mild Cognitive Impairment) that was fast, efficient, reliable and inexpensive.
- Wild, K., Howieson, D., Webbe, F., Seelye, A., Kaye, J. Status of computerized cognitive testing in aging: a systematic review
Alzheimers and Dementia, 4 (6), 428-437, 2008.
This is an independent review of 11 different computerized tests for Cognitive Decline. Each program rated in six different categories; Subtests, Normative Data, Reliability, Validity, Factor Analysis and Administration/Interface. A score of 1 to 3 was given for each category. The CANS-MCI test from Screen, Inc. had the highest total score and received special mention for exceptional usability with the elderly.
- Alzheimer’s Association New Annual Wellness Visits for Medicare Beneficiaries to Include Detection of Cognitive Impairment
The Centers for Medicare and Medicaid Services issued final regulations for implementation of an important provision of the Patient Protection and Affordable Care Act, which will include for the first time an annual wellness benefit for all Medicare beneficiaries beginning January 2011. The above link will take you to the original webpage. A PDF version of that page can be viewed here.
- Emory Hill, PhD, Jane B. Tornatore, PhD & Mary Reid, MD. Longitudinal Validity of a Mild Cognitive Impairment Screen: The CANS-MCI Study.
American Journal of Geriatric Psychiatry, Volume 16, No. 3, Supplement 1, A96-A97, March 2008. (Abstract)
- Jane B. Tornatore, PhD Emory Hill, PhD Jo Anne Laboff, MSW, Brian Fogel. One year Follow-Up Analyses of Scoring Algorithms for a Mild Cognitive Impairment Screen: The CANS-MCI Study
Alzheimer’s Association International Conference on Prevention of Dementia: Early Diagnosis and Intervention, Washington, D.C., June, 2005.
- Jane B. Tornatore, Ph.D., Emory Hill, Ph.D., Jo Anne Laboff, M.S.W. and Mary E. McGann, M.P.H., M.S.W. Self-Administered Screening for Mild Cognitive Impairment: Validation of a Computerized Test Battery
Journal of Neuropsychiatry and Clinical Neurosciences, Volume 17, No. 1, 98-105, Winter, 2005
- Jane B. Tornatore, PhD, Emory Hill, PhD, Jo Anne Laboff, MSW. The CANS-MCI: Self-administered Screening for Mild Cognitive Impairment.
Alzheimer’s and Dementia, 1, Suppl 1, 104, 2005. (Abstract)
- Emory Hill, PhD. Self-Administered Mild Cognitive Impairment Touch Screen Tests: The CANS-MCI Study.
Restorative Neurology and Neuroscience, 21, 5-6, 215, 2003. (Abstract)
- Jane B. Tornatore, PhD, Emory Hill, PhD. Validity of Self-Administered Mild Cognitive Impairment Touch Screen Tests.
Journal of Nutrition, Health and Aging, 7 (5), 315. 2003. (Abstract)
- Emory Hill, PhD, Ken Hammond MD. The Usability of Multimedia Automated Psychological Tests to Screen for Alzheimer’s Disease.
Proceedings of the American Medical Informatics Association Symposium 2000, 1030. (Abstract)